American Hospital Association Sues Trump Administration Over 340B Rebate Pilot

The American Hospital Association filed a federal lawsuit to halt a Trump administration pilot program that would replace upfront discounts in the 340B drug pricing program with an after-the-fact rebate model.

The Second Legal Challenge Against the 340B Rebate Pilot

The American Hospital Association is once again suing the Trump administration over its plan to test revamping a federal drug discount program into one that provides after-the-fact rebates instead of upfront discounts for certain drugs, statnews.com reported. It marks the second time the powerful hospital lobbying group has sued over such a plan. The first legal challenge occurred in 2025, when a judge agreed to temporarily halt a more limited version from taking effect. Following that preliminary setback, the Health and Human Services Department voluntarily withdrew the plan after losing on appeal.

The stakes have increased with the latest iteration announced in February. The agency introduced an expanded version set to take effect on January 1, 2027, that targets 25 of the costliest, most widely used drugs covered under Medicare. By comparison, the original pilot model included only 10 drugs.

Disputed Costs and Administrative Burdens for Hospitals

The core legal arguments presented by the hospital lobbying group remain largely consistent with the previous litigation. The American Hospital Association asserts that the government failed to accurately account for the costs hospitals would incur by having to pay full market prices for medications and subsequently applying for rebates.

According to the lawsuit, the Health Resources and Services Administration—the HHS division that administers the 340B program—received more than 2,400 comments on the rebate model’s second iteration. Submissions included hospitals describing in granular detail the catastrophic impact the transition would have.

Federal Officials Prepare Rebate Model Before 2027 Deadline

The unfolding legal battle sets up a direct confrontation over federal drug pricing mechanics ahead of the January 1, 2027, implementation date. While federal health officials move forward with preparations to test the rebate model across 25 high-cost Medicare drugs, hospital administrators and legal counsel continue to press federal courts to block the operational overhaul before financial obligations take effect.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.